Opioid Addiction Treatment Drug Surge... Market Cap Increased by 340 Billion Won in One Day

Indivior Pharmaceuticals Inc. (NASDAQ: INDV) closed at $35, up 5.33% on the most recent trading day. Its market capitalization climbed to approximately $4.37 billion (around 6 trillion KRW), with an intraday gain of roughly $246 million (about 340 billion KRW). Trading volume exceeded 2.2 million shares, marking elevated activity compared to its average.

In January, Indivior completed the relocation of its headquarters from the UK to the US and reorganized as a holding company. In late February, the company reported fourth-quarter 2025 results, driven by strong sales of its flagship long-acting injectable SUBLOCADE that exceeded market expectations, drawing investor attention. On April 30, Indivior will release first-quarter 2026 results and provide updates on its opioid use disorder treatment portfolio and cost-structure adjustments. The company has also disclosed additional real-world data demonstrating SUBLOCADE’s cost-saving benefits in clinical practice.

A specialty pharmaceutical firm spun off from the UK’s Reckitt Benckiser, Indivior is expanding its share of the US opioid-crisis market with its buprenorphine-based treatments SUBLOCADE and SUBOXONE. However, prior settlements totaling hundreds of millions of dollars over false-marketing allegations related to Suboxone underscore that litigation and regulatory risk management will remain critical factors influencing its share performance alongside growth prospects.